PHARMACIELO LTD (PCLO.CA) Stock News

PharmaCielo Cannabis Co. Reports 270% YoY Increase In Q3 Revenue, Confident About Profitability In 2025

Cannabis products company PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) announced on Monday financial and operational results for the three and nine months ended Sept. 30, 2024. The Toronto-based company said revenue for the third quarter totaled CA$1.3 million ($927,772), up from CA$352,000 in the prior year's period. For the nine months, total revenues reached CA$2.4 million, compared to CA$1.3 million in 2023. "PharmaCielo achieved substantial revenue growth, successfully expanded into new international markets, and continued its focus on reducing costs to improve its operational efficiency," Marc Lustig, chairman and CEO of PharmaCielo, said. "Our strategic position in multiple regions, coupled with an expanding product portfolio beyond CBD isolate, has enhanced our ability to serve diverse international markets and generate increased revenue."

PharmaCielo Cannabis Co. Sees 390% YoY Revenue Jump As Losses Narrow In Q2 2024

PharmaCielo Q2 2024 financial results: 390% revenue boost, improved net loss and strategic share issuance highlight growth and cost cuts.

IIROC Trading Resumption - PCLO.WT

IIROC Trading Halt - PCLO.WT

IIROC Trading Resumption - PCLO

IIROC Trading Halt - PCLO

IIROC Trading Resumption - PCLO

IIROC Trading Halt - PCLO

IIROC Trading Resumption - PCLO

IIROC Trading Halt - PCLO

PCLO Stock Up 1.58% After First European CBD Export

PharmaCielo Ltd. (TSXV:PCLO) (OTCPK:PHCEF) has today announced the successful completion of its first commercial export of CBD isolate to Europe. PCLO stock is up 1.58% as a result. Inaugural Shipment PharmaCielo is the ... Read